Ушбу иш иқтибос қилган ишлар

262 та иш

Иш: Tumor Microenvironment‐Responsive Nanomedicines for Potentiating Cancer Immunotherapy

Targeted nanomedicines remodeling immunosuppressive tumor microenvironment for enhanced cancer immunotherapy
Yanyan Xu, Jingyuan Xiong, Xiyang Sun +1
Шарҳ мақола20222 иқтибос
ABI
Towards precision medicine using biochemically triggered cleavable conjugation
Badri Parshad, Smriti Arora, Balram Singh +4
Шарҳ мақола20252 иқтибос
ABI
Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach?
Dunyaporn Trachootham, Jérôme Alexandre, Peng Huang
Шарҳ мақола20092 иқтибос
ABI
T cell exclusion, immune privilege, and the tumor microenvironment
Johanna A. Joyce, Douglas T. Fearon
Шарҳ мақола20152 иқтибос
ABI
Enzyme-responsive nanomaterials for controlled drug delivery
Quanyin Hu, Prateek S. Katti, Zhen Gu
Шарҳ мақола20142 иқтибос
ABI
Analysis of nanoparticle delivery to tumours
Stefan Wilhelm, Anthony J. Tavares, Qin Dai +4
Шарҳ мақола20162 иқтибос
ABI
Reactive‐Oxygen‐Species‐Responsive Drug Delivery Systems: Promises and Challenges
Gurusamy Saravanakumar, Jihoon Kim, Won Jong Kim
Шарҳ мақола20162 иқтибос
ABI
Elements of cancer immunity and the cancer–immune set point
Daniel S. Chen, Ira Mellman
Шарҳ мақола20172 иқтибос
ABI
Nanoparticles for modulating tumor microenvironment to improve drug delivery and tumor therapy
Shu Yang, Huile Gao
Шарҳ мақола20172 иқтибос
ABI
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Dung T. Le, Jennifer N. Durham, Kellie N. Smith +43
Мақола20172 иқтибос
ABI
TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
Sanjeev Mariathasan, Shannon J. Turley, Dorothee Nickles +39
Мақола20182 иқтибос
ABI
Defining ‘T cell exhaustion’
Christian U. Blank, W. Nicholas Haining, Werner Held +15
Шарҳ мақола20192 иқтибос
ABI
The dose threshold for nanoparticle tumour delivery
Ben Ouyang, Wilson Poon, Yi-Nan Zhang +11
Мақола20202 иқтибос
ABI
Applying high-dimensional single-cell technologies to the analysis of cancer immunotherapy
Satyen H. Gohil, J. Bryan Iorgulescu, David A. Braun +2
Шарҳ мақола20202 иқтибос
ABI
Off-the-Shelf Chimeric Antigen Receptor T Cells
Norihiro Watanabe, Maksim Mamonkin
Шарҳ мақола20212 иқтибос
ABI
Anti-angiogenic agents — overcoming tumour endothelial cell anergy and improving immunotherapy outcomes
Zowi R. Huinen, Elisabeth J. M. Huijbers, Judy R. van Beijnum +2
Шарҳ мақола20212 иқтибос
ABI
Modulation of the tumor micro-environment by CD8+ T cell-derived cytokines
Mirjam E. Hoekstra, Saskia V Vijver, Ton N. Schumacher
Шарҳ мақола20212 иқтибос
ABI
In Situ Tumor Vaccination with Nanoparticle Co‐Delivering CpG and STAT3 siRNA to Effectively Induce Whole‐Body Antitumor Immune Response
Worapol Ngamcherdtrakul, Moataz Reda, Molly A. Nelson +11
Мақола20212 иқтибос
ABI
Hypoxia and the Tumor Microenvironment
Yue Li, Long Zhao, Xiaofeng Li
Шарҳ мақола20212 иқтибос
ABI
Microenvironment‐Responsive Prodrug‐Induced Pyroptosis Boosts Cancer Immunotherapy
Yao Xiao, Tian Zhang, Xianbin Ma +6
Мақола20212 иқтибос
ABI
Desmoplastic Reaction, Immune Cell Response, and Prognosis in Colorectal Cancer
Naohiko Akimoto, Juha P. Väyrynen, Melissa Zhao +18
Мақола20222 иқтибос
ABI
NIR/pH-responsive chitosan hydrogels containing Ti3C2/AuNRs with NIR-triggered photothermal effect
Chongchong Liu, Panping Yang, Jingguo Li +2
Мақола20222 иқтибос
ABI
Reactive oxygen species-responsive polymer drug delivery systems
Jiaxue Liu, Boyan Jia, Zhibo Li +1
Шарҳ мақола20232 иқтибос
ABI
<scp>pH</scp>‐responsive polymers for drug delivery: Trends and opportunities
Jagtar Singh, Pallavi Nayak
Мақола20232 иқтибос
ABI
The cancer-immunity cycle: Indication, genotype, and immunotype
Ira Mellman, Daniel S. Chen, Thomas Powles +1
Шарҳ мақола20232 иқтибос
ABI